Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After football on WRAL: Patchy fog to start the school year. Where your kids will be likely to see it at the bus stop.
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Daiichi Sankyo Ltd ADR
(OP:
DSNKY
)
41.26
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Daiichi Sankyo Ltd ADR
< Previous
1
2
Next >
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
August 13, 2024
Daiichi Sankyo Co just reported results for the first quarter of 2024.
Via
InvestorPlace
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
August 07, 2024
"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say.
Via
Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
July 30, 2024
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...
Via
Benzinga
Exposures
Product Safety
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
July 15, 2024
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market.
Via
InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
June 27, 2024
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The...
Via
Benzinga
Exposures
Product Safety
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
Via
Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
January 13, 2023
Via
Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.
Via
Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
April 30, 2024
Daiichi Sankyo Co just reported results for the third quarter of 2023.
Via
InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
April 29, 2024
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Via
Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...
Via
Benzinga
Exposures
Product Safety
What's Going On With Pfizer Stock Today?
January 25, 2024
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.
Via
Benzinga
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says
September 12, 2022
Via
Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
January 03, 2024
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo...
Via
Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
December 20, 2023
Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth.
Via
Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
October 31, 2023
In due time, its new partnership with Daiichi Sankyo could be massive.
Via
The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:
Via
Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria
Via
Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
June 27, 2023
Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric...
Via
Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.
Via
The Motley Fool
AstraZeneca’s Next “Wonder Drug”
January 19, 2023
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key...
Via
Talk Markets
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
Via
Benzinga
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
December 09, 2022
Via
Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
November 14, 2022
Via
Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
Via
Benzinga
3 Top Stocks to Invest In Right Now
August 16, 2022
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense.
Via
InvestorPlace
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.